Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.89 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.89 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | BLK | P51451 | 1/20 | 0.74 |
| ▸ | BMX | P51813 | 1/20 | 0.74 |
| ▸ | JAK3 | P52333 | 1/20 | 0.74 |
| ▸ | BTK | Q06187 | 1/20 | 0.74 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213752 | 1.00 | EGFR (0.89) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2988658 | 0.94 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2988661 | 0.94 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2986126 | 0.89 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1417861 | 0.88 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL6586413 | 0.88 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1417862 | 0.88 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL6583797 | 0.88 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL6583800 | 0.88 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL28942731 | 0.88 | EGFR (0.88) | EGFRERBB2FYNSRCBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0980244-B1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH CORP (US) | 2003-06-04 | — | — | EP | claimed |
| US-6323209-B1 | QUINAZOLINE COMPOUNDS IN THE TREATMENT AND INHIBITION OF COLONIC POLYPS. | AMERICAN CYANAMID COMPANY | 2001-11-27 | — | — | US | claimed |
| EP-1039910-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | American Cyanamid Company (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0980244-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | American Cyanamid Company (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1999024037-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1998050038-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY (US) | 1998-11-12 | — | — | WO | claimed |
| EP-0787722-A1 | Substituted quinazoline derivatives | American Cyanamid Company (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0980244-B1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH CORP (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6323209-B1 | QUINAZOLINE COMPOUNDS IN THE TREATMENT AND INHIBITION OF COLONIC POLYPS. | AMERICAN CYANAMID COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1039910-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | American Cyanamid Company (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0980244-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | American Cyanamid Company (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1999024037-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1998050038-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0787722-A1 | Substituted quinazoline derivatives | American Cyanamid Company (US) | 1997-08-06 | — | — | EP | disclosed |